Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Who holds Processa Pharmaceuticals, Inc., from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Connective Capital Management, LLC | 85.3K | +20.6% | $163.7K | 0.1% | Aug 13, 2026 |
| Stonepine Capital Management, LLC | 55K | ±0% | $105.6K | 0.1% | Aug 17, 2026 |
| Geode Capital Management, LLC | 22.1K | −11.3% | $42.4K | 0% | Aug 12, 2026 |
| Citadel Advisors LLC | 21.3K | New | $40.9K | 0% | Sep 2, 2026 |
| StoneX Group Inc. | 11.4K | New | $29.6K | 0.1% | Aug 12, 2026 |
| XTX Topco Ltd | 13.3K | New | $25.5K | 0.1% | Aug 14, 2026 |
| Jane Street Group, LLC | 13.3K | New | $25.5K | 0% | Aug 14, 2026 |
| Vanguard Capital Management LLC | 12.7K | ±0% | $24.4K | 0% | Aug 13, 2026 |
| Vanguard Fiduciary Trust Co | 10.9K | ±0% | $20.8K | 0% | Aug 13, 2026 |
| UBS Group AG | 7.8K | +207.9% | $15K | 0% | Aug 13, 2026 |
| Tower Research Capital LLC (TRC) | 2.5K | +172.2% | $4.8K | 0.1% | Aug 11, 2026 |
| Jones Financial Companies LLLP | 7 | ±0% | $13 | 0% | Aug 14, 2026 |
